Biotech Investment Group Launches Formex, LLC

SAN DIEGO, July 19, 2013 /PRNewswire/ -- Biotech Investment Group. LLC ("BiG") and Formex, LLC ("Formex") announced today that BiG recently completed the asset purchase of PharmaForm and launched Formex, LLC, a leader in small molecule formulation for the pharmaceutical and biotechnolgy industry.

(Logo: http://photos.prnewswire.com/prnh/20130718/MM49948LOGO)

Having acquired the assets of PharmaForm, the Biotech Investment Group began operations of its newly created subsidiary, Formex, located in the Torrey Pines area of San Diego, California.

Formex, a leader in Hot Melt Extrusion, Spray Dried Dispersions and Drug Layering is poised to be the premier provider in the contract pharmaceutical formulation and clinical manufacturing service sectors. 

Formex has assembled an experienced scientific team of industry professionals with extensive knowledge in pharmaceutical formulation development and cGMP manufacturing of small molecule, solid dose products.

Formex currently utilizes 45,000 sq. ft. of its 80,000 sq. ft. facility in Torrey Pines, California

Formex has over 25,000 sq. ft. of cGMP clinical and commercial manufacturing space.  This includes 17 separate and dedicated cGMP suites.  Formex has suites qualified and dedicated for cytotoxic compound handling as well as potent compound handling.

The Formex facility has over 40,000 sq. ft. dedicated to R&D, analytical labs and cGMP ICH stability storage.

With temperature controlled cGMP warehouses and the entire facility on a dedicated backup generator system, Formex operates a world-class facility of cGMP and R&D labs that is among the best for a contract development and manufacturing organization (CDMO).

Situated on top of the hill in Torrey Pines, Formex is a proud neighbor and member of an elite community of biotechnology and pharmaceutical companies that dominate the San Diego landscape.

Building on the legacy of 18 years in the formulation and clinical trial manufacturing industry, Formex is elevating the standard for scientific ability, manufacturing capacity and standard of quality for small to mid-sized contract manufacturing organizations.

From Pre-Formulation for Solubilization Approach Selection, Formulation Development, Analytical Method Development, Analytical Testing, Pre-Clinical Manufacturing, cGMP Manufacturing for Phase 0-III Clinical Trials & Niche Commercial Product Manufacturing, Formex is your trusted outsourcing partner.

About Biotechnology Investment Group LLC.

Biotech Investment Group ("BiG"), founded in 2006, is a provider of growth equity capital to emerging healthcare services companies. BiG's mission is to partner with outstanding entrepreneurs to build long-lasting companies and deliver services which address significant unmet healthcare needs.  Current portfolio companies at the Biotechnology Investment Group are Molecular Response, LLC, Bio Atla, LLC, Femta, LLC and Formex, LLC.  For more information on BiG and their portfolio of healthcare companies pleases visit www.bioinv.com

About Formex LLC.

Formex LLC is a leading contract development and manufacturing organization focusing on oral and topical dosage forms.  Formex specializes in bioavailability enhancement and controlled release technologies, such as hot melt extrusion and spray drying.  Formex provides pre-formulation, formulation development, analytical method development, analytical testing, pre-clinical manufacturing, cGMP clinical trial manufacturing for Phase 0-III  & small scale commercial manufacturing.  Formex's currently occupies 45,000 sq. ft. of our 80,000 sq. ft.  facility with 25,000 sq. ft. of cGMP manufacturing space including 17 separate and dedicated cGMP suites including suites qualified and dedicated for cytotoxic compound handling as well as potent compound handling.

SOURCE Biotechnology Investment Group LLC; Formex LLC




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.